SMFM 2012 MultiPlayer Videos

The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.